Kefir improves bone mass and microarchitecture in an ovariectomized rat model of postmenopausal osteoporosis
- 1k Downloads
Kefir treatment in ovariectomized (OVX) rats could significantly decrease the levels of bone turnover markers and prevent OVX-induced bone loss, deterioration of trabecular microarchitecture, and biomechanical dysfunction that may be due to increase intracellular calcium uptake through the TRPV6 calcium channel.
Osteoporosis is a disease characterized by low bone mass and structural deterioration of bone tissue, leading to an increased fracture risk. The incidence of osteoporosis increases with age and occurs most frequently in postmenopausal women due to estrogen deficiency, as the balance between bone resorption and bone formation shifts towards increased levels of bone resorption. Among various methods of prevention and treatment for osteoporosis, an increase in calcium intake is the most commonly recommended preventive measure. Kefir is a fermented milk product made with kefir grains that degrade milk proteins into various peptides with health-promoting effects, including immunomodulating-, antithrombotic-, antimicrobial-, and calcium-absorption-enhancing bioactivities.
The aim of this study is to investigate the effect of kefir on osteoporosis prophylaxis in an ovariectomized rat model. A total of 56 16-week-old female Sprague-Dawley (SD) rats were divided into 7 experimental groups: sham (normal), OVX/Mock, OVX/1X kefir (164 mg/kg BW/day), OVX/2X kefir (328 mg/kg BW/day), OVX/4X kefir (656 mg/kg BW/day), OVX/ALN (2.5 mg/kg BW/day), and OVX/REBONE (800 mg/kg BW/day). After 12-week treatment with kefir, the bone physiology in the OVX rat model was investigated. Accordingly, the aim of this study was to investigate the possible transport mechanism involved in calcium absorption using the Caco-2 human cell line.
A 12-week treatment with kefir on the OVX-induced osteoporosis model reduced the levels of C-terminal telopeptides of type I collagen (CTx), bone turnover markers, and trabecular separation (Tb. Sp.). Additionally, treatment with kefir increased trabecular bone mineral density (BMD), bone volume (BV/TV), trabecular thickness (Tb. Th), trabecular number (Tb. N), and the biomechanical properties (hardness and modulus) of the distal femur with a dose-dependent efficacy. In addition, in in vitro assay, we found that kefir increased intracellular calcium uptake in Caco-2 cell through TRPV6 calcium channels and not through L-type voltage-operated calcium channels.
The protective effect of kefir in the OVX rat model may occur through increasing intracellular calcium uptake through the TRPV6 calcium channel.
KeywordsCalcium uptake Kefir Micro-CT Nanoindention Osteoporosis Ovariectomized rat
This research was supported in part by grants NSC101-2324-B-005-002-CC1 from the National Science Council and the Ministry of Education, Taiwan, Republic of China, under the Aiming for Top University plan (ATU-101-s0508). The authors would like to thank our colleague, Professor Jiunn-Wang Liao in the Graduate Institute of Veterinary Pathology, National Chung Hsing university, for his help with the discussions and technical issues.
Conflicts of interest
- 12.Chen HL, Tung YT, Tsai CL, Lai CW, Tsai HC, Lin YL, Wang CH, Chen CM (2014) Kefir improves fatty liver syndrome through inhibited lipogenesis pathway in leptin-deficient ob/ob knockout mice. Int J Obesity 38:1172–1179Google Scholar
- 20.Lin CW, Chen HL, Liu JR (1999) Identification and characterization of lactic acid bacteria and yeasts isolated from kefir grains in Taiwan. Aust J Dairy Technol 54:14–18Google Scholar
- 25.McCormack JG, Cobbold PH (1991) Cellular calcium: a practical approach. Oxford University Press, New York, NY, The practical approach seriesGoogle Scholar
- 29.Calvo MS, Eyre DR, Gundberg CM (1996) Molecular basis and clinical application of biological markers of bone turnover. Endocr Rev 17:33–368Google Scholar
- 31.Rosen HN, Moses AC, Garber J, Iloputaife ID, Ross DS, Lee SL, Greenspan SL (2000) Serum CTX: a new marker of bone resorption that shows treatment effect more than other markers because of low coefficient of variability and large changes with bisphosphonate therapy. Calcif Tissue Int 66:100–103PubMedCrossRefGoogle Scholar
- 34.Bouxsein ML (2003) Mechanisms of osteoporosis therapy: a bone strength perspective. Clin Cornerstone S13–S21Google Scholar
- 42.Yarrow JF, Conover CF, Purandare AV, Bhakta AM, Zheng N, Conrad B, Altman MK, Franz SE, Wronski TJ, Borst SE (2008) Supraphysiological testosterone enanthate administration prevents bone loss and augments bone strength in gonadectomized male and female rats. Am J Physiol Endocrinol Metab 295:E1213–E1222PubMedCrossRefGoogle Scholar
- 45.Bonjour JP, Benoit V, Payen F, Kraenzlin M (2013) Consumption of yogurts fortified in vitamin D and calcium reduces serum parathyroid hormone and markers of bone resorption: a double-blind randomized controlled trial in institutionalized elderly women. J Clin Endocrinol Metab 98:2015–2021CrossRefGoogle Scholar